

**SCHEDULING STATUS:** S4

**PROPRIETARY NAME AND DOSAGE FORM:**

LONITEN<sup>®</sup> 5 mg Tablets

LONITEN<sup>®</sup> 10 mg Tablets

**COMPOSITION:**

Each LONITEN 5 mg tablet contains 5 mg minoxidil.

Each LONITEN 10 mg tablet contains 10 mg minoxidil.

Excipients: lactose monohydrate, microcrystalline cellulose, corn starch, colloidal silicone dioxide, magnesium stearate.

**PHARMACOLOGICAL CLASSIFICATION:**

A 7.1 Vasodilators, hypertensive medicines

**PHARMACOLOGICAL ACTION:**

**Pharmacodynamic Properties**

*Therapeutic effect and mechanism of action*

Minoxidil lowers the elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance via vasodilation. The smooth musculature of the resistance vessels is the site of action for the relaxant effect of minoxidil. However, the biochemical mechanisms producing the reduction of the peripheral resistance have not yet been fully clarified. Minoxidil blocks the calcium intake in the cell membrane during depolarisation. Studies suggest that after the administration of minoxidil, secondary mechanisms are activated which then cause vasodilation.

### *Secondary Effects*

Sympathetic reflexes mediated by baroreceptors secondarily increase heart rate and myocardial contractility, thereby increasing cardiac output. In addition, the plasma rennin activity is increased via sympathetic nervous system stimulation, which results in an increased angiotensin II concentration with subsequent increased aldosterone secretion. In this way, the renal sodium excretion is reduced and extracellular volume increased. The pulmonary artery pressure may increase after the administration of minoxidil alone, but it decreases with the recommended concomitant therapy (beta-blocker plus diuretic).

### **Pharmacokinetic Properties**

#### *Absorption*

After oral administration in humans, at least 95 % of minoxidil is absorbed in the gastrointestinal tract. Minoxidil is detected within 15 - 30 minutes in the plasma. Maximum plasma levels are reached 30 - 60 minutes after administration.

#### *Protein binding*

Minoxidil is not bound to plasma proteins.

#### *Passage into cerebrospinal fluid*

Minoxidil does not cross the blood-brain barrier.

#### *Metabolism*

At least 90 % of the administered minoxidil are metabolised in the liver. The primary metabolite in humans is the minoxidil O-glucuronide. Some polar metabolites are also produced. The known metabolites have a weaker antihypertensive effect than the active ingredient itself.

#### *Biological half-life and elimination*

In humans, minoxidil plasma concentrations decrease with an average half-life of approx. 4 hours. However, the duration of action is over 24 hours up to 72 hours.

This disparity between blood level and pharmacological effect, and the large volume of distribution induces extensive tissue localisation of the drug.

However, on chronic treatment, accumulation does not occur and the pharmacological effect is slowly reversible. With an effective oral dose, blood pressure usually starts to decline within one-half hour, reaches a minimum between 2 and 3 hours, and recovers at a rate of approximately 30 % per day.

During daily administration, there is a cumulative effect which reaches a steady state after 3 to 7 days. The magnitude of the blood pressure response is related to the extent of the original diastolic elevation above 85 mmHg, and is proportional to the logarithmic function of dose administered. When the desired diastolic reduction is greater than 30 mmHg, twice a day dosing is advised to keep the diurnal variation within 10 mmHg.

Metabolites are excreted principally in the urine. Minoxidil and its metabolites are dialyzable. Haemodialysis does not, however, rapidly reverse the pharmacological effect of minoxidil.

The renal clearance of minoxidil corresponds to the glomerular filtration rate.

No substantial changes in the glomerular filtration rate and the renal plasma flow could be detected under minoxidil.

#### **INDICATIONS:**

Indicated as adjunctive therapy in adults with severe refractory hypertension which has failed to respond to extensive multiple therapy. LONITEN should be used concurrently with a sympathetic nervous system suppressant and a diuretic to initiate therapy.

#### **CONTRAINDICATIONS:**

LONITEN is contraindicated in:-

- pulmonary hypertension associated with mitral stenosis.
- patients with a known hypersensitivity to minoxidil or any of the ingredients of LONITEN.
- phaeochromocytoma.
- Pregnancy and lactation (see PREGNANCY AND LACTATION).
- Severe liver impairment.

## **WARNINGS AND SPECIAL PRECAUTIONS:**

### **Pericarditis, pericardial effusion and tamponade**

Pericarditis, pericardial effusion and tamponade, have been observed. LONITEN-treated patients should be periodically monitored for signs of symptoms of these events and, if found, appropriate therapy should be instituted. If the effusion persists, LONITEN should be withdrawn and other means of controlling the hypertension should be used.

Patients who have had a myocardial infarction should only be treated with LONITEN after a stable post-infarction state has been established.

### **Renal failure or dialysis patients**

Those patients with renal failure or on haemodialysis will require smaller doses of LONITEN. See DOSAGE AND DIRECTIONS FOR USE.

### **Dermatologic-hypertrichosis**

Elongation, thickening, and enhanced pigmentation of fine body hair have been seen in the majority of patients taking LONITEN. No endocrine abnormalities have been found to explain abnormal hair growth. All patients should be fully informed of this possible effect before commencing LONITEN therapy.

It is usually first noticed in the facial area within 3 to 6 weeks after starting therapy, and may recede slightly during prolonged therapy. Upon discontinuation of LONITEN, new hair growth stops, but it may take one to six months for restoration of pre-treatment appearance.

### **Altered laboratory findings**

*ECG changes* - A high percentage of patients exhibit ECG alterations in the direction and magnitude of their T-waves soon after starting LONITEN therapy. Large changes may encroach on the ST segment, but the ST segment is not independently altered and there is no evidence of myocardial ischemia. These asymptomatic changes usually disappear with continuing LONITEN treatment. The ECG reverts to the pre-treatment state if LONITEN is discontinued.

### **Salt and water retention**

If used alone, LONITEN can cause a significant retention of salt and water, producing dependent oedema; puffiness of face, eyes or hands; neck vein distention; hepatomegaly and a positive

hepatojugular reflux. Chest X-rays may show evidence of pulmonary vascular engorgement. LONITEN should be used in combination with a diuretic to prevent fluid retention oedema, and possibly congestive heart failure. The patient's body mass, fluid and electrolyte balance, should be monitored, and if there is evidence of fluid retention, the more vigorous diuretic treatment alone or in combination with restricted salt intake should be instituted.

Refractoriness to these measures may require temporary discontinuation of LONITEN therapy for 1 or 2 days, during which there may be partial loss of blood pressure control.

Salt and water retention in excess of 2,0 kg of weight gain may diminish the effectiveness of LONITEN, therefore, patients should be carefully instructed about compliance with diuretic usage and limitation of their electrolyte intake.

### **Tachycardia**

Because it is a vasodilator, reflex tachycardia may occur; angina pectoris may develop in patients with unsuspected coronary artery disease unless protected against LONITEN-induced

tachycardia with beta-adrenergic blocking drugs or other suitable sympathetic nervous system suppressants.

Patients with unstable angina pectoris or angina pectoris of recent onset should be protected with these agents before starting LONITEN therapy.

### **Lactose**

LONITEN contains lactose. LONITEN should not be administered to patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

### **General**

LONITEN is not recommended for the treatment of patients with labile or mild hypertension.

LONITEN should not be used for extended therapy in hypertension readily ameliorated by surgery, e.g. coarctation of the aorta, primary aldosteronism, or unilateral, large vessel renal artery stenosis.

### **Effects on Ability to Drive and Use Machines**

No studies on the effect of LONITEN on the ability to drive or use machines have been performed. The ability to drive or operate machinery may be influenced by the individual response to treatment, particularly at the start of therapy.

### **INTERACTIONS:**

The blood pressure lowering effect of LONITEN is additive to concurrent anti-hypertensive agents. The interaction of LONITEN with agents that produce orthostatic hypotension may result in excessive blood pressure reduction.

### **PREGNANCY AND LACTATION:**

#### **Pregnancy**

LONITEN is contraindicated during pregnancy and in women of childbearing potential not using contraception. There is limited data from the use of LONITEN in pregnant women. Studies in animals have shown reproductive toxicity (see CONTRAINDICATIONS).

### **Lactation**

LONITEN has been reported to be excreted in milk. A risk to the suckling child cannot be excluded. LONITEN should not be used by women who are breastfeeding their babies.

### **DOSAGE AND DIRECTIONS FOR USE:**

The usual adult dosage range of LONITEN is 5 to 40 mg/day. The maximum recommended dosage is 100 mg/day.

LONITEN therapy can be initiated with a single or divided daily dosage. If the desired reduction in diastolic pressure is greater than 30 mmHg, divided dosage will minimize diurnal fluctuations.

Dosage adjustments should be made at intervals of 3 days or longer.

A more rapid reduction of pressure can be achieved using continuous blood pressure monitoring and incremental doses of 5 mg every 6 hours. Dosage requirements may be lower in patients undergoing chronic dialysis. Prior to introducing LONITEN, it is recommended that the antihypertensive therapy be adjusted to a regimen consisting of a diuretic and beta-adrenergic blocking agent. When other sympathetic nervous system suppressants are used, the initial dosage of LONITEN should be reduced.

### **Patients over 12 years of age:**

Initial dosage: 5 mg as a single or divided daily dosage.

Incremental increases: 5 - 10 mg/day, at 3-day intervals, until 50 mg/day is reached; then in increments of 25 mg/day up to a maximum of 100 mg/day.

### **Concomitant therapy:**

Diuretics:

LONITEN must be given with sufficient diuretic therapy to maintain salt and water balance in all patients who are on dialysis. When excessive water retention results in a weight gain exceeding 2 kg, the type of diuretic should be changed or an aldosterone antagonist should be added. In children, diuretic dosage should be proportional to body weight.

**Sympathetic nervous system suppressants:**

Initially, most patients will require a sympathetic nervous system suppressant to limit a LONITEN-induced rise in heart rate.

The preferred agent is a beta-blocker equivalent to an adult propranolol dosage of 80 - 160 mg/day. Higher doses may be required when pretreated patients have an increase in heart rate exceeding 20 beats/minute or when simultaneous introduction causes an increase exceeding 10 beats/minute. When beta-blockers are contra-indicated, methyldopa or clonidine may be used instead and should be started 24 hours prior to LONITEN.

**Renal failure or dialysis patients**

Those patients with renal failure or on haemodialysis may require smaller doses of LONITEN. See DOSAGE AND DIRECTIONS FOR USE.

**SIDE EFFECTS:**

The table below contains side-effects categorised as follows utilising the incidence rates: Very common  $\geq 1/10$  ( $\geq 10\%$ ); Common  $\geq 1/100$  and  $< 1/10$  ( $\geq 1\%$  and  $< 10\%$ ); Rare  $\geq 1/10\ 000$  and  $< 1/1000$  ( $\geq 0,01\%$  and  $< 0,1\%$ ); Frequency unknown (cannot be estimated from available data).

<b>MedDRA System Organ Class</b>	<b>Frequency</b>	<b>Undesirable Effect</b>
Blood and lymphatic system disorders	Rare	leukopenia, thrombocytopenia
	Frequency unknown	decline in haemoglobin, decline in haematocrit, blood urea increase, hypotension
Metabolism and nutrition disorders	Common	fluid retention, puffiness of face, eyes or hands
Cardiac disorders	Very common	tachycardia, pericarditis
	Common	pericardial effusion, cardiac tamponade
	Frequency unknown	angina pectoris
Skin and subcutaneous tissue disorders	Very common	hypertrichosis, hair colour changes
	Rare	Stevens-Johnson syndrome, dermatitis bullous, rash
Investigations	Very common	electrocardiogram
	Common	angina pectoris
	Frequency unknown	temporary rise in creatinine
Vascular	Frequency unknown	neck vein distension, positive hepatojugular reflux, pulmonary vascular engorgement
Hepato-biliary disorders	Frequency unknown	hepatomegaly

<b>MedDRA System Organ Class</b>	<b>Frequency</b>	<b>Undesirable Effect</b>
Gastrointestinal disorders	Frequency unknown	gastrointestinal intolerance
Reproductive system and breast disorders	Frequency unknown	breast tenderness, gynaecomastia, polymenorrhoea

**KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:**

Hypotension may occur. Recommended treatment is intravenous administration of normal saline. Sympathomimetic agents, such as noradrenaline or adrenaline, should be avoided because of their excessive cardiac-stimulating action. Phenylephrine, angiotensin II, and vasopressin which reverse the effects of LONITEN should only be used if inadequate perfusion of a vital organ is evident.

**IDENTIFICATION:**

Loniten 5 mg and 10 mg tablets are round white tablets.

Loniten 5 mg tablets are imprinted with a "5" on one side of the tablet with a "U" with a "score" and then "U" on the other side of tablet.

Loniten 10 mg tablets are imprinted with a "10" on one side of the tablet with a "U" with a "score" and then "137" on the other side of tablet.

**PRESENTATION:**

Bottles of 100 tablets containing 5 mg or 10 mg.

**STORAGE INSTRUCTIONS:**

Store between 15 °C and 30 °C. Protect from light.

KEEP OUT OF REACH OF CHILDREN.

**REGISTRATION NUMBERS:**

LONITEN 5 mg: N/7.1/165

LONITEN 10 mg: N/7.1/166

**NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF  
REGISTRATION:**

Pfizer Laboratories (Pty) Ltd

85 Bute Lane

Sandton

2196

**DATE OF PUBLICATION OF THIS PACKAGE INSERT:**

27 November 2015